Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 7;11(4):393-396.
doi: 10.1093/ehjcvp/pvaf029.

News in cardiovascular pharmacotherapy from the ACC.25 Meeting

Eva Delpón  1 , Ricardo Caballero  1 , Juan Tamargo  1
Affiliations

News in cardiovascular pharmacotherapy from the ACC.25 Meeting

Eva Delpón et al. Eur Heart J Cardiovasc Pharmacother. .

Abstract

Summary of some of the most relevant clinical trials on cardiovascular pharmacotherapy presented at the ACC.25. Clinical trial acronyms are shown in parenthesis with capital letters.

Keywords: ACC.25; Cardiovascular drugs; Clinical trials.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: none declared.

Figures

Graphical Abstract
Graphical Abstract
Summary of some of the most relevant clinical trials on cardiovascular pharmacotherapy presented at the ACC.25. Clinical trial acronyms are shown in parenthesis with capital letters.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Nissen SE, Ni W, Shen X, Wang Q, Navar AM, Nicholls SJ, Wolski K, Michael L, Haupt A, Krege JH, ALPACA Trial Investigators . Lepodisiran. A long-duration small interfering RNA targeting lipoprotein(a). N Engl J Med 2025;392:1673–1683. 10.1056/NEJMoa2415818 - DOI - PubMed
    1. Ray KK, Oru E, Rosenson RS, Jones J, Ma X, Walgren J, Haupt A, Verma S, Gaudet D, Nicholls SJ, Ruotolo G. Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3):?a double-blind, randomised, lacebo-controlled, phase 2 trial. Lancet 2025;405:1594–1607. - PubMed
    1. Koren MJ, Vega RB, Agrawal N, Xu Y, Barbour AM, Yu H, Wallerstedt E, Carter D, Middlemiss J, Twaddle L, McCarthy MC, Rosenmeier JB. An oral PCSK9 inhibitor for treatment of hypercholesterolemia: the PURSUIT randomized trial. J Am Coll Cardiol 2025:S0735-1097(25)05907-8. - PubMed
    1. Xie X, Shi X, Zhang Y, Su S, Jiang C, Miao L, Junkui W, Daoquan P, Lingchun L, Xiaohong C, Suxin L, Yang Z, Shan H, Dan Z, Shangshang L, Meng R, Xiaohong G, Haibo Y, Hao Z, Yuquan H, Yajun H, Jiahong X, Zhang Lin DL, Zhuhua Y, Jianlong S, Xiaoping P, Xiaowen C, Juxiang L, Jie M, Qiang L, Hongju W, Zheng S, Zhilin Z, Feng G, Chao L, Min Z, Ying Z, Wang J. Angiopoietin-like 3 antibody therapy in patients with suboptimally controlled hyperlipidemia: a phase 2 study. J Am Coll Cardiol 2025;85:1821– 1835. 10.1016/j.jacc.2025.03.008 - DOI - PubMed
    1. Laffin LJ, Kopjar B, Melgaard C, Wolski K, Ibbitson J, Bhikam S, et al. Advance-HTN investigators. Lorundrostat efficacy and safety in patients with uncontrolled hypertension. N Engl J Med 2025;392:1813–1823. - PubMed